BackRecro Pharma Overview

Recro Pharma Current Cash

Latest current cash for REPH: $8.1M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$8.10M
↓ 46.02% YoYΔ $-6.90M vs prior year quarter

Peer average

Loading

Recro Pharma Current Cash History

Loading

Recro Pharma vs. peers: Current Cash Comparison

Loading

Recro Pharma Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Recro Pharma (REPH) FAQ

Recro Pharma (REPH) currently reports a current cash of $8.1M as of December 2023. That compares with $15M in the prior-year period — down 46.0% year over year. Use the charts on this page to explore Recro Pharma's current cash history and peer comparisons.

Recro Pharma's current cash decreased from $15M to $8.1M — a 46.0% year-over-year decrease (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Recro Pharma reported $8.1M in current cash as of December 2023. That compares with $15M in the prior-year period — down 46.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $8.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Recro Pharma, and consider following REPH for alerts when major investors trade the stock.

Recro Pharma is classified in the Healthcare sector. On current cash, it currently shows $8.1M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing REPH with unrelated industries.